Бұл баяндамада Апиынды алмастыруды емдеудің (ОСТ) Еуропа елдерінде қалай жүзеге асырылып жатқаны қаралады және ОСТ рецептілік дәрі-дәрмектерін бөлудің және мақсатсыз пайдаланудың халық денсаулығына тигізетін салдары зерттеледі.

Онда ОСТ дәрі-дәрмектерінің заңсыз нарыққа қалай бағытталатыны, бұру мен мақсатсыз пайдаланудың уәждері қаралады, сондай-ақ диверсияның алдын алу жөніндегі шараларды және олар емдеудің мұқтаж адамдар үшін қолжетімді және қолжетімді болып қалуын қалай қамтамасыз ету керектігін қарастырады.

Objective: To explore innovative programmes providing solutions in the field of homelessness and drugs.

Background: The association between long-term homelessness, problem drug use and alcohol dependence are well documented. Evidence suggests that a relatively small, long-term and recurrently homeless population has a high prevalence of mental health problems and substance dependence. In the context of the current COVID-19 pandemic, there is much concern that the health and social wellbeing of members of this population will worsen. Addressing their diverse and complex needs is...

The Pompidou Group calls for youth projects to submit applications for the 2021 edition of the European Drug Prevention Prize.

The Prevention Prize is awarded to highlight outstanding drug prevention projects that have proved successful in involving young people in their design, implementation and evaluation.

Up to three projects will be awarded a Prize. During the Award Ceremony, each will receive the Prize Trophy, the Prize Diploma and €5.000 to support implementation. Prize-winners tell us that winning the Prize has helped them gain greater recognition for their work.

The deadline for...

The purpose of this technical report is to provide an analysis of the available information on methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dimethylbutanoate (commonly known as 4F-MDMB-BICA), a synthetic receptor cannabinoid agonist that has recently emerged on the drug market in Europe, in order to support the risk assessment of the substance which has been requested by the European Commission.

Table of contents

1. Summary
2. Background
3. Chemical and physical properties, methods and the precursors used for manufacture or extraction
4. Legitimate use
5. Pharmacological and...

The focus in this webinar is the links between alcohol and cancer and the forthcoming Europe Beating Cancer Plan.

In this brochure, the EMCDDA's Scientific Director takes us on a journey through 25 years of annual reporting on the drugs problem in Europe.

The journey begins with the first report describing the drug situation in 1995 and leads us, over key milestones, to the latest European Drug Report 2020.

Looking back on a quarter of a century of annual reporting, two things stand out: first, Europe's drugs problem has evolved considerably over this period; and second, this evolution has been accompanied by a dramatic increase in the quantity and quality of the information available on the topic.

The...